AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAR 14 - (NewsRx.com & NewsRx.net) -- A Mayo Clinic study indicates long-term use of the antidepressant drug venlafaxine provides women treated for breast cancer with safe and effective relief from hot flashes. It also appears that this antidepressant can be an alternative to estrogen for women who want a nonhormonal treatment for their hot flashes.
This follow-up study showed that women receiving venlafaxine over eight weeks maintained approximately a 60% reduction in their hot flashes. A total of 102 postmenopausal women participated in this investigation. The findings of the eight-week evaluation mirrored the results of the first phase of this study - a four-week double-blinded, randomized study that involved more than 200 women.
The results of the study are published in Oncology Nursing Forum.
"The clear message is that now many women with breast cancer do not have to suffer with their hot flashes and that women who want a nonestrogenic choice of treatment now have one," said Charles Loprinzi, MD, a Mayo Clinic oncologist.
"The study also further reassures physicians and other health care providers that venlafaxine is a safe and effective nonhormonal treatment they can consider for their postmenopausal patients."
Loprinzi coauthored this study with Debra L. Barton, PhD, a Mayo Clinic oncology nurse researcher.
"We know from our previous study that venlafaxine works in the short term to control hot flashes," said Barton. "This follow-up study provides evidence that venlafaxine continues to be effective and ...
Source: HighBeam Research, Venlafaxine safe, effective for women with and without breast cancer.